Recombinant interleukin 2 (IL-2, aldesleukin) was approved for the treatment of metastatic melanoma and renal cell carcinoma over two decades ago (Noble and Goa, 1997; Wrangle et al., 2018). The gene discussed is IL2; the disease is renal cell carcinoma.